Viraday Tablet

Viraday Tablet. Viraday Tablet is a nucleoside reverse transcriptase inhibitor (NRTI) which is used for treating HIV infection This drug filters out the HIV from the blood it does not cure the disease but is helpful in preventing AIDS It comes as a capsule a tablet and a solution Do not use Viraday Tablet.

Viraday Tablet is used for Hiv Hiv infection Hepatitis b virus and other conditions Viraday Tablet may also be used for purposes not listed in this medication guide Viraday Tablet contains Efavirenz Emtricitabine and Tenofovir as active ingredients Viraday Tablet works by lowering the growth and decreasing the amount of HIV virus in the 44/5 (17).

Viraday Tablet: View Uses, Side Effects, Price and

Viraday Tablet is a combination of antiretrovirals medicines It is prescribed to treat HIV (human immunodeficiency virus) infection It boosts up the immunity to fight against HIV to manage or treat AIDS (acquired immunodeficiency syndrome) Viraday Tablet restricts the growth of HIV in the body and reduces the risk of getting HIVrelated.

Viraday Tablet Product TabletWise.com

Posology and Method of AdministrationContraindicationsSpecial Warnings and Precautions For UseUndesirable EffectsOverdoseTesting Prior to Initiation and During Treatment with VIRADAYTablets Prior to or when initiating VIRADAY Tablets test patients for HBV (hepatitis B virus) infection Prior to initiation and during use of VIRADAY Tablets on a clinically appropriate schedule assess serum creatinine estimated creatinine clearance urine glucose and urine protein in all patients In patients with chronic kidney disease also assess serum phosphorus Monitor hepatic function prior to and during treatment with VIRADAY Tablets Perform pregnancy testing before initiation of VIRADAY Tabletsin adults of childbearing potential Recommended Dosage for Adults Patients Weighing at Least 40 kg VIRADAYTablets is a threedrug fixeddose combination product containing 600 mg of efavirenz (EFV) 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF) The recommended dosage of VIRADAYTabletsin adults weighing at least 40 kg is one tablet once daily taken orally on an empty stomach Dosin VIRADAY Tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (eg StevensJohnson syndrome erythema multiforme or toxic skin eruptions) to EFV a component of VIRADAY Tablets VIRADAY Tabletsare contraindicated for coadministration with voriconazole or elbasvir/grazoprevir Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV1 and HBV All patients should be tested for the presence of chronic HBV before or when initiating antiretroviral therapy Severe acute exacerbations of hepatitis B (eg liver decompensation and liver failure) have been reported in patients who are coinfected with HBV and HIV1 and have discontinued FTC and TDF two of the components of VIRADAY Tablets Patients who are coinfected with HIV1 and HBV should be closely monitored with both clinical and laboratory followup for at least several months after stopping treatment with VIRADAY Tablets If appropriate initiation of antihepatitis B therapy may be warranted especially in patients with advanced liver disease or cirrhosis since posttreatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure Rash In controlled clinical trials 26% (266/1008) of subjects treated with 600 mg EFV experienced newonset skin rash compared wit The following adverse reactions have been discussed in other sections of the labeling Severe Acute Exacerbations of Hepatitis B in Patients Coinfected with HIV1 and HBV Rash Hepatotoxicity Psychiatric Symptoms Nervous System Symptoms NewOnset or Worsening Renal Impairment EmbryoFetal Toxicity Bone Loss and Mineralization Defects Convulsions Lactic Acidosis/Severe Hepatomegaly with Steatosis Immune Reconstitution Syndrome Fat Redistribution Clinical Trials Experience Because clinical trials are conducted under widely varying conditions adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice Clinical Trials in Adult Subjects STUDY 934 Study 934 was an openlabel activecontrolled trial in which 511 antiretroviralnaïve subjects received either FTC + TDF administered in combination with EFV (N=257) or zidovudine/lamivud If overdose occurs the patient should be monitored for evidence of toxicity including monitoring of vital signs and observation of the patient’s clinical status standard supportive treatment should then be applied as necessary Administration of activated charcoal may be used to aid the removal of unabsorbed EFV Hemodialysis can remove both FTC and TDF (refer to detailed information below) but is unlikely to significantly remove EFV from the blood EFV Some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms One patient experienced involuntary muscle contractions FTC Hemodialysis treatment removes approximately 30% of the FTC dose over a 3hour dialysis period starting within 15 hours of FTC dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min) It is not known whether FTC can be removed by peritoneal dialysis TDF Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximate.